Toggle Offcanvas
...
 
Infliximab Tenders

Infliximab Tenders

View Infliximab tenders, RFPs and contracts. Bid on readily available Infliximab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Infliximab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Infliximab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Infliximab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Infliximab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

35 Live Notices for Infliximab Tenders

Showing 1 to 20

Open House Contracts 2025-1
country Germany
posting date11 Mar 2025
deadline02 May 2025
Delivery Of Laboratory Reagents And Consumables For Diagnostic Tests And Lease Of Analyzers And Other Equipment.
country Poland
posting date11 Mar 2025
deadline10 Apr 2025
Medicinal Product With The Active Substance Infliximab Reopening
country Czech Republic
posting date11 Mar 2025
deadline30 May 2025
Delivery Of Laboratory Reagents And Consumables For Diagnostic Tests And Lease Of Analyzers And Other Equipment.
country Poland
posting date06 Mar 2025
deadline10 Apr 2025
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Subcutaneous Application
country Germany
posting date01 Mar 2025
deadline10 Feb 2027
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Intravenous Application
country Germany
posting date01 Mar 2025
deadline10 Feb 2027
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Subcutaneous Application
country Germany
posting date28 Feb 2025
deadline10 Feb 2027
Request For Information: Equipment And Reagents For The Analysis Of Biological Drug Assays
country Finland
posting date26 Feb 2025
deadline01 May 2025
Open House Biologics Discount Agreements 2025-01 - Infliximab
country Germany
posting date13 Feb 2025
deadline31 Mar 2027
Open House Biologics Discount Agreements 2025-01 - Infliximab
country Germany
posting date13 Feb 2025
deadline31 Mar 2027
Drugs For Biological Therapy 2025
country Slovakia
posting date11 Feb 2025
deadline17 Mar 2025
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
country Germany
posting date05 Dec 2024
deadline05 Dec 2026
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
country Germany
posting date26 Nov 2024
deadline05 Dec 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
country Germany
posting date11 Nov 2024
deadline31 Dec 2026
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date11 Nov 2024
deadline02 Nov 2026

Share Share this page